Correspondence 0001104659-24-005879 from ArriVent Biopharma, Inc. (AVBP) (CIK 0001868279) (AVBP)
ArriVent Biopharma, Inc. (AVBP) (CIK 0001868279)
Date: Jan. 23, 2024 · CIK: 0001868279 · Accession: 0001104659-24-005879
AI Filing Summary & Sentiment
File numbers found in text: 333-276397
Letter
Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282-2198
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Citigroup Global Markets Inc.
383 Greenwich Street
New York, New York 10013
January 23, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christopher Edwards
Suzanne Hayes
Division of Corporation Finance
Office of Life Sciences
Re: ArriVent BioPharma, Inc.
Registration Statement on Form S-1
File No. 333-276397
Acceleration Request
Requested Date: January 25, 2024
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of ArriVent BioPharma, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 5:00 P.M., Eastern Time, on January 25, 2024, or as soon thereafter as practicable or at such later time as the Company or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we, as representatives of the several underwriters, will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP
1
filename1.htm
Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282-2198
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Citigroup Global Markets Inc.
383 Greenwich Street
New York, New York 10013
January 23, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Christopher Edwards
Suzanne Hayes
Division of Corporation Finance
Office of Life Sciences
Re: ArriVent BioPharma, Inc.
Registration Statement on Form S-1
File No. 333-276397
Acceleration Request
Requested Date: January 25, 2024
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives
of the several underwriters, hereby join in the request of ArriVent BioPharma, Inc. (the “Company”) for acceleration
of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 5:00 P.M., Eastern Time, on January 25,
2024, or as soon thereafter as practicable or at such later time as the Company or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C., may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please
be advised that we, as representatives of the several underwriters, will take reasonable steps to secure adequate distribution of the
preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the
several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied
and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
GOLDMAN SACHS & CO. LLC
By:
/s/ Lyla Maduri
Name: Lyla Maduri
Title: Managing Director
JEFFERIES LLC
By:
/s/ Charles Glazer
Name: Charles Glazer
Title: Managing Director
CITIGROUP GLOBAL MARKETS INC.
By:
/s/ Lin Yan
Name: Lin Yan
Title: Managing Director
[Signature
Page to Underwriters’ Acceleration Request]